{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:21:37Z","timestamp":1784082097578,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-024-02944-1","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T20:20:45Z","timestamp":1727295645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Investigation of Mirabegron-loaded Nanostructured Lipid Carriers for Improved Bioabsorption: Formulation, Statistical Optimization, and\u00a0In-Vivo\u00a0Evaluation"],"prefix":"10.1208","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1057-2566","authenticated-orcid":false,"given":"Pranav","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashwini","family":"Kansara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavin","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pintu","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhulika","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"2944_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/nau.10099","volume":"22","author":"G Digesu","year":"2003","unstructured":"Digesu G, Khullar V, Cardozo L, et al. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22:105\u20138. https:\/\/doi.org\/10.1002\/nau.10099.","journal-title":"Neurourol Urodyn"},{"key":"2944_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"W Stewart","year":"2003","unstructured":"Stewart W, Rooyen V, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327\u201336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4.","journal-title":"World J Urol"},{"key":"2944_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11884-016-0344-9","volume":"11","author":"W Reynolds","year":"2016","unstructured":"Reynolds W, Fowke J, Dmochowski R. The burden of overactive bladder on US public health. Curr Bladder Dysfunct Rep. 2016;11:8\u201313. https:\/\/doi.org\/10.1007\/s11884-016-0344-9.","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"2944_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/01.NPR.0000422213.00175.5d","volume":"37","author":"J Belavic","year":"2012","unstructured":"Belavic J. Mirabegron for overactive bladder. Nurse Pract. 2012;37:9\u201310. https:\/\/doi.org\/10.1097\/01.NPR.0000422213.00175.5d.","journal-title":"Nurse Pract"},{"key":"2944_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/2042098616659412","volume":"7","author":"K Warren","year":"2016","unstructured":"Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7:204\u201316. https:\/\/doi.org\/10.1177\/2042098616659412.","journal-title":"Ther Adv Drug Saf"},{"key":"2944_CR6","doi-asserted-by":"publisher","unstructured":"Iitsuka H, Van Gelderen M, Katashima M, et al. Pharmacokinetics of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects. 2015;37:1031\u201344. https:\/\/doi.org\/10.1007\/s40261-013-0146-1.","DOI":"10.1007\/s40261-013-0146-1"},{"key":"2944_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/pharmaceutics10030149","volume":"10","author":"JH An","year":"2018","unstructured":"An JH, Lim C, Kiyonga AN, et al. Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors. Pharmaceutics. 2018;10:149. https:\/\/doi.org\/10.3390\/pharmaceutics10030149.","journal-title":"Pharmaceutics"},{"key":"2944_CR8","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.52711\/0974-360X.2022.00244","volume":"15","author":"R Surawase","year":"2022","unstructured":"Surawase R, Baheti K. Box Behnken design for optimization of mirabegron solid dispersion by fluidised bed processing. Res J Pharm Technol. 2022;15:1472\u20136. https:\/\/doi.org\/10.52711\/0974-360X.2022.00244.","journal-title":"Res J Pharm Technol."},{"key":"2944_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/2211738509666210127143107","volume":"9","author":"P Raut","year":"2021","unstructured":"Raut P, Gambhire M. Development and Optimization of Mirabegron Solid Lipid Nanoparticles as an oral drug delivery for overactive bladder. Pharm Nanotechnol. 2021;9:120\u20139. https:\/\/doi.org\/10.2174\/2211738509666210127143107.","journal-title":"Pharm Nanotechnol"},{"key":"2944_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/4687959","volume":"2023","author":"A Mahor","year":"2023","unstructured":"Mahor A, Singh P, Gupta R, et al. Nanostructured lipid carriers for improved delivery of therapeutics via the oral route. J Nanotechnol. 2023;2023:1\u201335. https:\/\/doi.org\/10.1155\/2023\/4687959.","journal-title":"J Nanotechnol"},{"key":"2944_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ijpharm.2008.01.045","volume":"357","author":"C Puglia","year":"2008","unstructured":"Puglia C. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295\u2013304. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.01.045.","journal-title":"Int J Pharm"},{"key":"2944_CR12","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.2147\/IJN.S41521","volume":"8","author":"AA Khan","year":"2013","unstructured":"Khan AA, Mudassir J, Mohtar N. Advanced drug delivery to the lymphatic system: lipid-based nano-formulations. Int J Nanomed. 2013;8:2733\u201344. https:\/\/doi.org\/10.2147\/IJN.S41521.","journal-title":"Int J Nanomed"},{"key":"2944_CR13","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/pharmaceutics15061593","volume":"15","author":"C Viegas","year":"2023","unstructured":"Viegas C, Patr\u00edcio AB, Prata JM, et al. Solid lipid nanoparticles vs. nanostructured lipid carriers: A comparative review. Pharmaceutics. 2023;15:1593. https:\/\/doi.org\/10.3390\/pharmaceutics15061593.","journal-title":"Pharmaceutics."},{"key":"2944_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2174\/1567201817666200708115627","volume":"18","author":"P Shah","year":"2020","unstructured":"Shah P, Sarolia J, Vyas B, Wagh P, Kaur A, Mishra A. PLGA nanoparticles for nose to brain delivery of clonazepam formulation, optimization by 32 factorial design in vitro and in vivo evaluation. Curr Drug Deliv. 2020;18:805\u201324. https:\/\/doi.org\/10.2174\/1567201817666200708115627.","journal-title":"Curr Drug Deliv"},{"key":"2944_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.17756\/nwj.2015-015","volume":"1","author":"K Dhoranwala","year":"2015","unstructured":"Dhoranwala K, Shah P, Shah S. Formulation optimization of rosuvastatin calcium-loaded solid lipid nanoparticles by 32 full-factorial design. NanoWorld J. 2015;1:110\u20139. https:\/\/doi.org\/10.17756\/nwj.2015-015.","journal-title":"NanoWorld J."},{"key":"2944_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"X Meng","year":"2011","unstructured":"Meng X, Zhang H, Mezei M, et al. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7:146\u201357. https:\/\/doi.org\/10.2174\/157340911795677602.","journal-title":"Curr Comput Aided Drug Des"},{"key":"2944_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.colsurfb.2013.10.018","volume":"114","author":"J Luan","year":"2014","unstructured":"Luan J, Zhang D, Hao L, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf B Biointerfaces. 2014;114:255\u201360. https:\/\/doi.org\/10.1016\/j.colsurfb.2013.10.018.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2944_CR18","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.2147\/IJN.S215835","volume":"14","author":"M Kim","year":"2019","unstructured":"Kim M, Kim K, Sohn S, et al. Formulation and evaluation of nanostructured lipid carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) by box-behnken design. Int J Nanomedicine. 2019;14:8509\u201320. https:\/\/doi.org\/10.2147\/IJN.S215835.","journal-title":"Int J Nanomedicine"},{"key":"2944_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5409387","volume":"7","author":"V Sharma","year":"2016","unstructured":"Sharma V, Sharma P, Kumar V. In silico molecular docking analysis of natural pyridoacridines as anticancer agents. Adv Chem. 2016;7:1\u20139. https:\/\/doi.org\/10.1155\/2016\/5409387.","journal-title":"Adv Chem"},{"key":"2944_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ijpharm.2015.09.054","volume":"495","author":"J Baek","year":"2015","unstructured":"Baek J, Pham C, Myung C, et al. Tadalafil-loaded nanostructured lipid carriers using permeation enhancers. Int J Pharm. 2015;495:701\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.054.","journal-title":"Int J Pharm"},{"key":"2944_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1208\/s12249-021-02099-3","volume":"22","author":"K Borderwala","year":"2021","unstructured":"Borderwala K, Rathod S, Shah P. Eudragit S 100 surface engineered nanostructured lipid carriers for colon targeting of 5 fluorouracil: optimization and in vitro and in vivo characterization. AAPS PharmSciTech. 2021;22:216\u201322. https:\/\/doi.org\/10.1208\/s12249-021-02099-3.","journal-title":"AAPS PharmSciTech"},{"key":"2944_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/10717540903431586","volume":"17","author":"LJ Jia","year":"2010","unstructured":"Jia LJ, Zhang DR, Li ZY, et al. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv. 2010;17:11\u20138. https:\/\/doi.org\/10.3109\/10717540903431586.","journal-title":"Drug Deliv"},{"key":"2944_CR23","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s13204-021-01744-4","volume":"11","author":"S Dasineh","year":"2021","unstructured":"Dasineh S, Akbarian M, Ebrahimi H, et al. Tacrolimus-loaded chitosan-coated nanostructured lipid carriers: preparation, optimization and physicochemical characterization. Appl Nanosci. 2021;11:1169\u201381. https:\/\/doi.org\/10.1007\/s13204-021-01744-4.","journal-title":"Appl Nanosci"},{"key":"2944_CR24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.xphs.2021.02.018","volume":"110","author":"N Chokshi","year":"2021","unstructured":"Chokshi N, Rawal S, Solanki D, et al. Fabrication and characterization of surface engineered rifampicin loaded lipid nanoparticulate systems for the potential treatment of tuberculosis: an in vitro and in vivo evaluation. J Pharm Sci. 2021;110:2221\u201332. https:\/\/doi.org\/10.1016\/j.xphs.2021.02.018.","journal-title":"J Pharm Sci"},{"key":"2944_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12247-008-9023-5","volume":"3","author":"JF MacGregor","year":"2008","unstructured":"MacGregor JF, Bruwer M-J. A framework for the development of design and control spaces. J Pharm Innov. 2008;3:15\u201322. https:\/\/doi.org\/10.1007\/s12247-008-9023-5.","journal-title":"J Pharm Innov"},{"key":"2944_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nano.2017.05.014","volume":"13","author":"T Bastogne","year":"2017","unstructured":"Bastogne T. Quality-by-design of nano-pharmaceuticals - a state of the art. Nanomedicine. 2017;13:1\u20139. https:\/\/doi.org\/10.1016\/j.nano.2017.05.014.","journal-title":"Nanomedicine."},{"key":"2944_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/pharmaceutics11020097","volume":"11","author":"AA Khan","year":"2019","unstructured":"Khan AA, Mudassir J, Akhtar S, Murugaiyah V, Darwis Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11:97. https:\/\/doi.org\/10.3390\/pharmaceutics11020097.","journal-title":"Pharmaceutics"},{"key":"2944_CR28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.xphs.2019.10.007","volume":"109","author":"L Zhao","year":"2019","unstructured":"Zhao L, Tang B, Tang P, et al. Chitosan\/Sulfobutylether-b-cyclodextrin nanoparticles for ibrutinib delivery: a potential nano formulation of novel kinase inhibitor. J Pharm Sci. 2019;109:1136\u201344. https:\/\/doi.org\/10.1016\/j.xphs.2019.10.007.","journal-title":"J Pharm Sci"},{"key":"2944_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3109\/03639040903485716","volume":"36","author":"X-L Zhao","year":"2010","unstructured":"Zhao X-L, et al. Preparation and characterization of nanostructured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil. Drug Dev Ind Pharm. 2010;36:773\u201380. https:\/\/doi.org\/10.3109\/03639040903485716.","journal-title":"Drug Dev Ind Pharm."},{"key":"2944_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jchromb.2012.01.018","volume":"887","author":"R Van Teijlingen","year":"2012","unstructured":"Van Teijlingen R, Meijer J, Takusagawa S, et al. Development and validation of LC\u2013MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B. 2012;887:102\u201311. https:\/\/doi.org\/10.1016\/j.jchromb.2012.01.018.","journal-title":"J Chromatogr B"},{"key":"2944_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.colsurfb.2017.11.064","volume":"162","author":"H Fathi","year":"2018","unstructured":"Fathi H, Allam A, Elsabahy M, et al. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B. 2018;162:236\u201345. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.11.064.","journal-title":"Colloids Surf B"},{"key":"2944_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00345-019-02939-9","volume":"38","author":"T Majima","year":"2020","unstructured":"Majima T, Matsukawa Y, Funahashi Y, et al. The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction. World J Urol. 2020;38:1\u201312. https:\/\/doi.org\/10.1007\/s00345-019-02939-9.","journal-title":"World J Urol"},{"key":"2944_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1590\/1806-9282.65.2.141","volume":"65","author":"L Chen","year":"2019","unstructured":"Chen L, Zheng Y. Determination of Mirabegron in rat plasma by UPLC-MS\/MS after oral and intravenous administration. Revista Da Associacoa Medico Brasileira. 2019;65:141\u20138. https:\/\/doi.org\/10.1590\/1806-9282.65.2.141.","journal-title":"Revista Da Associacoa Medico Brasileira"},{"key":"2944_CR34","doi-asserted-by":"publisher","first-page":"8553","DOI":"10.2147\/IJN.S274352","volume":"15","author":"R Awadeen","year":"2020","unstructured":"Awadeen R, Boughdady M, Meshali M. Quality by design approach for preparation of zolmitriptan\/chitosan nanostructured lipid carrier particles-formulation and pharmacodynamic assessment. Int J Nanomedicine. 2020;15:8553\u201368. https:\/\/doi.org\/10.2147\/IJN.S274352.","journal-title":"Int J Nanomedicine"},{"key":"2944_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3109\/10837450.2013.867445","volume":"20","author":"L Mandpe","year":"2015","unstructured":"Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol. 2015;20:320\u20139. https:\/\/doi.org\/10.3109\/10837450.2013.867445.","journal-title":"Pharm Dev Technol"},{"key":"2944_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0973-8398.134921","volume":"8","author":"H Thakkar","year":"2014","unstructured":"Thakkar H, Desai J, Parmar M. Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil. Asian J Pharm. 2014;8:81\u20139. https:\/\/doi.org\/10.4103\/0973-8398.134921.","journal-title":"Asian J Pharm"},{"key":"2944_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0939-6411(97)00150-1","volume":"45","author":"Z M\u00fchlen","year":"1998","unstructured":"M\u00fchlen Z, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery\u2013drug release and release mechanism. Eur J Pharm Biopharm. 1998;45:149\u201355. https:\/\/doi.org\/10.1016\/s0939-6411(97)00150-1.","journal-title":"Eur J Pharm Biopharm"},{"key":"2944_CR38","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","volume":"1","author":"A Khosa","year":"2018","unstructured":"Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;1:598\u2013613. https:\/\/doi.org\/10.1016\/j.biopha.2018.04.055.","journal-title":"Biomed Pharmacother"},{"key":"2944_CR39","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.3390\/molecules27103190","volume":"27","author":"K Ladan","year":"2022","unstructured":"Ladan K, Glava\u010d K. Statistical FT-IR spectroscopy for the characterization of 17 vegetable oils. Molecules. 2022;27:3190. https:\/\/doi.org\/10.3390\/molecules27103190.","journal-title":"Molecules"},{"key":"2944_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.colsurfa.2013.03.070","volume":"430","author":"M Zheng","year":"2013","unstructured":"Zheng M, Falkeborg M, Zheng Y, et al. Formulation and characterization of nanostructured lipid carriers containing a mixed lipids core. Colloids Surf A. 2013;430:76\u201384. https:\/\/doi.org\/10.1016\/j.colsurfa.2013.03.070.","journal-title":"Colloids Surf A"},{"key":"2944_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijpharm.2006.01.022","volume":"314","author":"A Saupe","year":"2006","unstructured":"Saupe A, Gordon K, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm. 2006;314:56\u201362. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.01.022.","journal-title":"Int J Pharm"},{"key":"2944_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jare.2016.03.002","volume":"7","author":"N Shah","year":"2016","unstructured":"Shah N, Seth A, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J Adv Res. 2016;7:423\u201334. https:\/\/doi.org\/10.1016\/j.jare.2016.03.002.","journal-title":"J Adv Res"},{"key":"2944_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3109\/21691401.2014.909820","volume":"44","author":"G Patil","year":"2016","unstructured":"Patil G, Patil N, Deshmukh P, et al. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach. Artif Cells Nanomed Biotechnol. 2016;44:12\u20139. https:\/\/doi.org\/10.3109\/21691401.2014.909820.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2944_CR44","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s13346-020-00839-9","volume":"11","author":"P Shah","year":"2020","unstructured":"Shah P, Chavda K, Vyas B, et al. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. Drug Deliv Transl Res. 2020;11:1166\u201385. https:\/\/doi.org\/10.1007\/s13346-020-00839-9.","journal-title":"Drug Deliv Transl Res"},{"key":"2944_CR45","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1038\/s41598-017-02523-4","volume":"7","author":"A Sattar","year":"2017","unstructured":"Sattar A, Chen D, Jiang L, et al. Preparation, characterization and pharmacokinetics of cyadox nanosuspension. Sci Rep. 2017;7:2289\u2013310. https:\/\/doi.org\/10.1038\/s41598-017-02523-4.","journal-title":"Sci Rep"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-024-02944-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:08:54Z","timestamp":1729696134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-024-02944-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1208\/s12249-024-02944-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No humans were utilized in this research work.\u00a0The caution and use of laboratory animals was conducted in according with all institution and national guidelines. The study protocol number was MPC\/IAEC\/05\/2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Participation Consent"}},{"value":"The permission to publish has been granted by each author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The writers state that no disclosed conflicts of interest exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"222"}}